Sign Up Today and Learn More About Curegene Stock
Invest in or calculate the value of your shares in Curegene or other pre-IPO companies through EquityZen, part of Morgan Stanley.
Curegene Stock (CURG)
Curegene focuses on the treatment of anti-viral diseases as well as cardiovascular and cerebrovascular diseases.
About Curegene Stock
Founded
2018
Industries
Software, Artificial Intelligence, Data and Analytics
Curegene Press Mentions
Stay in the know about the latest news on Curegene
Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight
globenewswire • Jul 30, 2026
First participant receives Evategrel in CureGene’s trial
clinicaltrialsarena • Jun 23, 2026
CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization
biospace • Jun 22, 2026
CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization
prnewswire • Jun 21, 2026
CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization
morningstar • Jun 21, 2026
Join now and verify your accreditation status to gain access to:
- Curegene Current Valuation
- Curegene Stock Price
- Curegene Management
- Available deals in Curegene and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Curegene Cap Table and Funding History by Share Class and Liquidity Preferences
- Curegene Revenue and Financials
- Curegene Highlights
- Curegene Business Model
- Curegene Risk Factors
- Curegene Research Report from SACRA Research
Trading Curegene Stock
How to invest in Curegene stock?
Accredited investors can buy pre-IPO stock in companies like Curegene through EquityZen funds. These investments are made available by existing Curegene shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Curegene stock?
Shareholders can sell their Curegene stock through EquityZen's private company marketplace. EquityZen's network includes over 480K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 56K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
